National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on MRP of 137 anti-cancer drugs, based on the recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under Ministry of Health & Family Welfare on 17th October, 2026. The revised prices of these drugs will come into effect from 9th November, 2026.
As on date, 76 pharmaceutical companies have reported revised MRP for 1225 anti-cancer formulations, covering 121 drugs. Reduction in the MRP have been reported in 1031 formulations of anti-cancer medicines, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%. Further, out of the 137 identified anti-cancer drugs, there are 10-15 drugs which are yet to be launched in India. However, Trade Margin Rationalization (TMR) will be applicable on these drugs also as and when they are launched.
As a result of the price reductions to be effected from 9th November, 2026, the estimated annual savings to consumers would be ₹3,502.31 crore.
List of major anti-cancer brands with revised prices
Bevacizumab 100 MG Injection: Used for Lung, Colon, Ovary and Cervical Cancer
Denosumab 60 MG Injection: Used for breast and prostate cancer (prevents bone loss)
Abiraterone acetate 250 MG Tablet: Used for Prostate Cancer
Pegfilgrastim 6 MG Injection: To prevent neutropenia in cancer patients
Azacitidine 100 MG Injection: Used for Blood Cancer
Enzalutamide 40 MG Capsule: Used for prostate cancer
Fulvestrant 250 mg Injection: Used for breast cancer
Palbociclib 125 MG Capsule: Used for breast cancer
Pemetrexed 500 MG Vial: Used for lung cancer
Pertuzumab 420 MG Injection: Used for breast cancer
TMR of non-scheduled anti-cancer medicines is an important step taken by the Government in its continued efforts to improve affordability and accessibility of essential anti-cancer medicines for cancer care.
The notification SO 5690 (E ) dated 17th October, 2026 will remain in force until further orders However, manufacturers can avail annual price increase in accordance with the provisions of Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, subject to continued compliance with the maximum permissible trade margin of 30%
Every retailer, dealer, hospital and institution is required to prominently display Revised MRP list of anti-cancer medicines on their websites and in their premises. As per the NPPA notification, State Drug Controllers will monitor compliance by manufacturers, dealers, Hospitals and Medical Institutions. Consumers can check the applicable prices through the Pharma Sahi Daam mobile application and the NPPA website (www.nppa.gov.in) and report any non-compliance or violation of revised prices to the authority.
Complaints can be submitted through the following channels:
Post: Deputy Director, Monitoring, NPPA, 3rd Floor, YMCA Cultural Centre Building, 1 Jai Singh Marg, New Delhi – 110001.